EQS Group

RESULTS HIGHLIGHTS:● The Revenue for the six months ended 30 June 2024 (“the Period”) was approximately HK$1,701.8 million, representing an increase of about 6.3% compared to the same period last year. Notably, the major European market accounted for 48.4% of the Group's total, with sales growing by 16.2% compared to the same period last year.● The Gross Profit Margin for the Period was approximately 53.7%, with a gross profit of about HK$914.0 million, represents an increase of approximately 5.4% compared to the same period last year.● The Group’s Adjusted EBITDA for the Period was approximately HK$388.6 million, representing an increase of approximately 5.1% as compared to the same period last year.● The profit from the Group's core business for the Period was approximately HK$225.5 million, representing a growth rate of 7.2% compared to the same period last year. ● The Group’s Net Profit for the Period was approximately HK$214.4 million, representing an increase of approximately 1.9% as compared to the same period last year.● With respect to the Group’s EBITDA and Net Profit for the Period, it should be noted that the figures reflect: (i) one-off cost in connection with potential acquisitions of approximately HK$2.8 million; and (ii) one-off cost in connection with Shenzhen and Vietnam production facility relocations of approximately HK$10.2 million.● Basic earnings per share for the six months ended 30 June 2024 amounted to HK$22.59 cents.● The Board declared an interim dividend of HK8.0 cents per ordinary share for the six months ended 30 June 2024.● During the period under review, The Group’s digital solution cases (overseas and domestic) that are produced from its Mainland China production facilities increased to approximately 602,485 cases reflecting an increase of 61.1% as compared with the same period in 2023 as a result of our clients’ continued adoption of intra-oral scanners.(29 August 2024, Hong Kong) - Modern Dental Group Limited (hereinafter referred to as "Modern Dental Group" or "the Group", stock code: 03600.HK”), a leading global dental prosthetics provider, is pleased to announce the unaudited interim results for the six months ended 30 June 2024 (“the Period”).During the six months ended 30 June 2024, although the macro-economic environment continues to be challenging, the Group’s multi-dimensional strategies and comprehensive products portfolio, encompassing higher-priced and cost-effective dental treatments, enabled the Group to capitalize on market opportunities by capturing new customers and increase its sales volume, displaying the Group’s ability to outperform its competitors throughout the economic cycle. The consolidation trend of the dental prosthetics industry is clearly continuing, and with the addition of our Vietnam production facility and Dongguan Phase 2 production facility - the Group has further improved its market positioning.The Group’s continued sales increase represents a solid execution across each of the Group’s markets operationally and financially, illustrating the Group’s ability to deliver strong financial results in a relatively stable operating environment characterized by consistent order volume growth, competitiveness in the industry, and close relationship with its clients and customers. The Group’s underlying fundamentals continue to be solid and we are well-positioned to capture further opportunities going forward.European BusinessDuring the period under review, the European market recorded a revenue of approximately HK$822.9 million, representing an increase of approximately HK$112.9 million as compared with the six months ended 30 June 2023. This geographic market accounted for approximately 48.4% of the Group’s total revenue. The increase of revenue from the European market was attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner providing comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources.North American BusinessDuring the period under review, the North American market recorded a revenue of approximately HK$385.3 million. This geographic market accounted for approximately 22.6% of the Group’s total revenue.Our clients’ interest surrounding digital dentistry continued to increase during the period. A significant portion of our business in the North America region comprises higher-end products manufactured domestically. With our centralized digital workflows and network oversight over our wide coverage of production units within the region, we are well positioned to support the customers’ needs through their digitalization journey, focusing on leveraging efficiencies and providing an enhanced customer experience throughout the network. Looking forward, the Group targets to utilize the Vietnam production facility to establish a new business unit specialized in serving mid/large scale dental clinic chains customers in the North American market.Greater China BusinessDuring the period under review, the Greater China market recorded a revenue of approximately HK$335.8 million. This geographic market accounted for approximately 19.7% of the Group’s total revenue. As a result of the increase in sales volume in the Mainland China market following the full implementation of the volume-based procurement policy in the Mainland China market gradually since the second half of 2023, our Mainland China business reported a sales growth of 9.5% in the Period compared to the same period last year but is offset by the depreciation of RMB against HK$ by 2.7%. However, this also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong).The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessDuring the period under review, the Australian market recorded a revenue of approximately HK$127.9 million representing an increase of approximately HK$3.6 million as compared with the six months ended 30 June 2023. This geographic market accounted for approximately 7.5% of the Group’s total revenue. The increase of revenue from the Australian market was predominately due to the increase in sales volume as a result of the increase in market share driven by the digitalization trend in dental industry which is partially offset by the depreciation of AUD against HK$ by 2.8% compared with the six months ended 30 June 2023.Through our various brands, which offer onshore-and offshore- made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market.Future ProspectsIt is expected that the Group continues to consolidate the dental prosthetic market, and the Board is of the view that the consolidation trend is irreversible and clearly continuing. Therefore, notwithstanding any short- or medium-term challenges the global economy may face, the Board is confident that the Group is expected to outperform its competitors. In a year where some of the Group’s competitors had faced materially adverse issues, the Group continued to thrive and it is the Group’s ability to thrive during such uncertain economic conditions that give the Board comfort in its optimistic view of the Group.Going forward, the Group aims to reinforce its worldwide leading position through opportunistic transactions including strategic co-operations, acquisitions, joint ventures and/or partnerships, to further expand and complement our product-offering (in particular, our clear aligner products), distribution and sales networks which will in turn, drive our business expansion. The Group continues to grow into more than just a one-stop shop dental prosthetic provider, but a full dental ecosystem to support our customers. The Group’s investment in Dongguan phase 2 and Vietnam production facilities are expected to provide the Group with greater production solutions and optionality which will in turn, increase the Group’s level of research and development in further enhancing our production and products.Looking forward to 2024, with the Board’s extensive experience and determination to meet any short-term challenges, the Group is in an ideal position to take full advantage of, and will remain opportunistic in, any business opportunities whilst remaining cautious and prudent in safeguarding shareholders’ interests.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA in the United States, and Southern Cross Dental in Australia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 23 countries and serve over 30,000 customers.30/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

On August 28th, Huitongda Network Co., Ltd. (9878. HK) released its financial report for the first half of 2024, when the company proactively adjusted its development strategy to focus on optimizing its industrial structure and promote high-quality business development. According to the financial report, Huitongda Network recorded a total revenue of 32.86 billion yuan and a net profit attributable to the parent company of 130 million yuan; The quality of operation has steadily improved, with a gross profit margin of 3.5%, an increase of 0.5 percentage points compared to the same period last year.Uncertainties in the global macroeconomy are on the rise and consumption growth falls short of expectations in the first half of 2024. The retail sales of consumer goods in China totaled RMB 23.6 trillion for the half year, with per capita disposable income of urban residents increasing by 4.6% and per capita disposable income of rural residents increasing by 6.8%, according to the National Bureau of Statistics of China.The income and consumption growth rate of rural residents in domestic lower-tier markets is better than that of urban markets, but demand is still under pressure in the short term. Given the severe situation, Huitongda Network takes "improving quality and efficiency in transformation and innovation" as its general principle for the year, actively adjusts its industrial structure and improves operational efficiency to further promote business transformation and upgrading.Huitongda Network, the industrial Internet leader exploring expansion into lower-tier retail market, served for family-run stores in villages and towns through the empowerment of digital technology and supply chain capacity. For one thing, the Group created a stable and efficient one-stop supply chain and provides multi-category transaction services; For another, by empowering upstream and downstream partners in the urban-rural industrial chain through digitization, it provided services such as SaaS+ services and merchant solutions. At present, the Group has formed a retail ecosystem covering 24,000 townships in 21 provinces and municipalities directly under the central government in China. Its main products focused on the "three high categories" of high product value, high offline experience, and high after-sales requirements, covering seven major categories of consumer electronics, household appliances, agricultural means of production, vehicles and auto parts merchandise, liquor and beverages, home building and renovation materials, and personal care.In the commerce business sector, the Group has steadily improved its supply chain capacity, achieving a revenue of 32.39 billion yuan during the reporting period. According to the financial report, the Group has over 246,000 registered member retail stores as of the end of June 2024, a year-on-year increase of 13.2%; Over 92,000 active member retail stores, a year-on-year increase of 19.3%. The revenue of member retail stores has increased to 43.8% compared to the same period last year, further strengthening the control over downstream channels.In constructing supply chain capacity, the Group focused on brand cooperation, integrated production and marketing, and market expansion in the first half of the year, improving the efficiency of the entire industry chain. In respect of brand cooperation, the company deepened cooperation with leading brands in seven major sectors including household appliances, consumer electronics, and vehicles and auto parts merchandise, while expanding cooperation with resource-based and regional retail enterprises; In respect of integrating production and marketing, the company has established an innovative supply chain model and taken the lead in incubating integrated production and marketing projects in the home appliance and agricultural means of production industries, greatly improving the efficiency of the supply chain and the output of commercial business value. Among them, the self-owned brand "IDISSA" air conditioner launched in the first half of the year exceeded 16000 sets of orders in just two weeks, setting the "ultimate cost-effectiveness" label for the lower-tier market. Moreover, the Group has expanded into areas such as home cleaning, personal care, and photovoltaics while consolidating existing business, striving to improve gross profit levels and promote sustainable growth.In the service business sector, the Group continued efforts to strengthen the capacity for serving members, achieving a revenue of 380 million yuan in the first half of the year, a year-on-year increase of 12.0%. According to the financial report, the Group accumulated over 127,000 SaaS+ subscription users in the first half of the year, a year-on-year increase of 5.1% and nearly 48,000 paid SaaS+ users, a year-on-year increase of 28.8%, along with store SaaS+ subscription revenue of RMB 310 million, a year-on-year increase of 13.6%. The loyalty of member retail stores further improved.Focusing on upgrading product value, the Group further strengthened its capacity for serving members during the reporting period. In product upgrades sector, the Group promoted further upgrading of SaaS+ products, gaining market recognition in efficiently empowering digital management of stores and targeted marketing strategy advice for members; In membership services sector, joint promotional activities were carried out with brand owners and manufacturers in the first half of the year, with a total of 6 national sales promotions, and more than 27,000 store-based personalized activities; In customer development sector, continuous progress has been made in the key customer service strategy, and deep cooperation has been established with over 60 domestic service enterprise customers, brand owners, and chain merchants.In respect of digital construction, the Group continued to upgrade its industrial trading platform in the first half of the year, launching functions such as merchant live streaming rooms and price inquiry and trading of products. It also promoted technological innovation and strengthened the application of cutting-edge technology to enhance the AI review of products and achieve automatic generation of product description, ensuring fast listing while improving service efficiency.Regarding the shareholder returns, the Group actively followed the government's initiative in the form of favorable returns to investors based upon the new "National Nine Articles" (short for Opinions on Strengthening Regulation to Prevent Risks and Promote High-Quality Development of Capital Markets, which consists of nine parts). In July, a proposal was passed to formulate a Shareholder Dividend Return Plan for the Next Three Years (2024-2026) and amend the Group's articles of association, opening a window for the implementation of the shareholder dividend return plan in the next three years.Since its listing, Huitongda Network stays committed to the mission of "making farmers' lives better", developing the low-tier market while promoting rural revitalization. On the one hand, the Group deepened the empowerment of rural talents and conducted training for over 20000 new farmers in the first half of this year; On the other hand, it fully integrated digital technology into the real economy in the low-tier market through applying digital technology in rural development. The Group's industrial Internet mode has been reported by the "People's Daily", "Xinhua News Agency" and other national media for many times during the reporting period. Meanwhile, its business value has also been recognized by the capital market after being included in the MSCI World Small Cap Index, and listed as the "Fortune China 500" for three consecutive years.Huitongda Network stated that looking ahead, the Group will adhere to sustainable and high-quality development by focusing on four core competencies: supply chain capability, brand operation capability, platform service capability, and organizational construction capability, to improve the operational efficiency of member retail stores, thereby promoting further upgrading of urban and rural industrial ecosystem, while promoting rural revitalization and high-quality development of digital villages.30/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Newborn Town sees a net profit growth of 28% to RMB 388 million, total revenue surpassed 65% for the first half of 2024, whilst the MENA market revenue surged by over 44%On August 29, Newborn Town (09911. HK) unveiled its interim results for the first half of 2024, demonstrating significant growth in various key operational indicators. The improvement was driven by its skyrocketing pan-audience social networking business and further expansion in the MENA market.According to the announcement, Newborn Town reported a total revenue of RMB 2,272 million for the first half of 2024, marking a substantial 65% period-on-period increase. Net profit for the period reached RMB 388 million, up 28% period-on-period. Profit attributable to the owners of the Company was RMB 225 million, reflecting a 21% period-on-period rise. Adjusted EBITDA totaled at RMB 448 million, demonstrating a 29% period-on-period increase. The social networking business segment attained robust growth, achieving revenue of approximately RMB 2,070 million, marking a 67% growth period-on-period. Additionally, the innovative sector made significant progress, recording revenue of around RMB 202 million, reflecting a 54% period-on-period growth.Notably, the Company's long-term investment in the MENA region has been yielding positive feedback. The capability for "product replication "has been further strengthened, with new products represented by SUGO rapidly maturing, thus bringing fresh growth momentum to the Company. As one of the major markets, the MENA market has consistently been the core focal point of the Company’s strategic implementation of localization strategy. Through years of in-depth regional operations, Newborn Town has built up a comprehensive regional organization, nurtured a local team of employees, and forged strong connections with local creators and partners. The benefits brought about by Newborn Town's localization efforts are becoming increasingly evident. For the first half of 2024, the MENA market contributed over 50% of the company's social networking business revenue, with the core products recording a 44% period-on-period increase.The MENA region has also been the market for Newborn Town's new business incubation. Products with high potential, such as TopTop and SUGO, have been successfully scaled up from inception as their business models were verified for global market expansion.This August, Saudi Arabia's Ministry of Investment granted Newborn Town a Regional Headquarters (RHQ) license, making it the world's first social entertainment company to establish a regional headquarter in Saudi Arabia. This move further consolidates Newborn Town's efforts in the MENA region.Under the RHQ program, Newborn Town will aim to build a trustworthy enterprise in the MENA region through close connections with governments, active engagement in community development and charitable activities, serving the local populace and building an ecosystem. While continuously widening the moat with its localization strength, Newborn Town has also achieved significant breakthroughs in product operation, starting to achieve the goal of replicating the popular apps that generate tens of millions of dollars in monthly revenue. After MICO, the companion-based social app SUGO has reached the target.Newborn Town's operation strategy, centered on cultivating the "Bushes" housing apps with diverse features, has been developed through a deep understanding of users' specific social and entertainment needs. Under this strategy, Newborn Town's strength in app operation has steadily advanced, alongside enhancements in the middle platform mechanism.Moreover, the company's aggregated localized operation resources have hastened the emergence of hit apps by facilitating swift product launches, cost-effective trial and error testing, and highly efficient verification.SUGO and TopTop, the new apps under Newborn Town, have both experienced explosive revenue growth. SUGO, for example, has achieved an over 250% period-on-period increase in revenue. In July, SUGO contributed the majority revenue to Newborn Town among the apps.TopTop, the social gaming platform with a double period-on-period revenue increase in the first half, was featured as a recommendation on the Apple App Store in May, reaching users across dozens of countries and regions, including Saudi Arabia, the United Arab Emirates, and Oman.The first-mover products, such as MICO and YoHo, have also made significant strides. MICO, TopTop, SUGO, and YoHo all ranked on Sensor Tower's Top 10 highest-grossing social apps in MENA from January to May 2024.According to the announcement, the company will persist in its pursuit of creating successful products in increasingly specialized niches and duplicating more apps that yield monthly revenues in the tens of millions of US dollars.Beyond its achievements in pan-audience social networking business, Newborn Town’s other business segments have also seen notable progress.HeeSay, the LGBTQ+ online community, has strengthened its global brand presence through more refined in-app operations. Since early this year, this platform has launched a series of offline events in Bangkok, Ho Chi Minh City, Los Angeles, etc., fostering a stronger sense of community among users. These efforts have contributed to an increase in business scale of approximately 25%.In addition, the company has continued investment in developing quality games. In the first half of 2024, Newborn Town's quality games achieved a recharge of RMB 387 million, up 393% period-on-period. Its flagship title, Alice's Dream: Merge Games, secured a spot among Sensor Tower's top 30 Chinese mobile games in overseas revenue for May and June.Overall, Newborn Town has made significant strides across key markets and various business segments in the first half of 2024. The company has reinforced the validity of its business models in the social sector, bolstering the competitiveness of its new products and injecting new growth catalysts.Moving forward, Newborn Town aims to delve deeper into the social entertainment realm, gaining a foothold in MENA and expanding globally to create positive emotional values.File: FINAL-赤子城科技公布中期業績_en_2024082930/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Ficus Technology Holdings Limited(Incorporated in the Cayman Islands with limited liability)(Stock Code: 8107)Entering into a Cooperation Agreement with the subsidiary of China Supply and Trade GroupTo Synergise Channel and Supply Chain Resources(Hong Kong - 29 August 2024) Innovative supply chain management service provider –Ficus Technology Holdings Limited (“Ficus Technology” or the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 29 August 2024, Ficus Discovery (www.ficusdsc.com, “Ficus Discovery Platform”), the e-commerce platform operated by the Group is collaborating with Beijing New Cooperation Ruida Trade Co., Ltd.* (“Beijing Ruida”) for a period of three years. As a direct wholly-owned subsidiary of China Supply and Trade Group and an indirect wholly-owned subsidiary of China CO-OP Group Co., Ltd., Beijing Ruida is primarily engaged in provision of supply chain services, operation of supermarket and other business in the retail industry.Leveraging its supply chain resources, including access to local products and local brands as well as its extensive supermarket and retail network, Beijing Ruida will provide products and supply chain services to Ficus Discovery Platform. This strategic partnership will allow both parties to synergise their channel resources, enhance product diversity and expand customer base across both online and offline channels. About Ficus Discovery Platform Ficus Discorvery Platform is an e-commerce platform operated by the Group, utilizing a disintermediation model to establish direct connections between manufacturers and consumers (“M2LC”), thereby facilitating transactions and cultivating a long-term loyal customer base. Leveraging the Group’s extensive supply chain resources, innovative supply chain management solutions, digital marketing capabilities, authentication and traceability technologies, the Ficus Discovery Platform is well-positioned to be a trustworthy gateway for brands and manufacturers to access target customers.Mr. Chan Ting, Chairman and Executive Director of Ficus Technology Holdings Limited comments: “Ficus Discovery Platform is pleased to work with Beijing Ruida on providing products to consumers in both the e-commerc platform we operated and the retail channels of Beijing Ruida’s platform. The collaboration not only enables Ficus Discovery Platform to diversify its product offerings but, more importantly, provides the Group with valuable access to the sales channels of the China Supply and Trade Group. We are confident that this collaboration will significantly elevate Ficus Discovery Platform's presence among consumers, establishing it as the preferred destination for daily necessities. Additionally, this partnership will amplify the brand value for both parties, driving mutual growth and market influence.”- END -About Ficus Technology Holdings Limited（8107.HK）Ficus Technology Holdings Limited (formerly known as Vision International Holdings Limited) is an innovative supply chain management service provider, mainly focuses on the sales of apparel products with the provision of supply chain management services. The Group had advanced supply chain management service to include anti-counterfeit, traceability and marketing functions for brand protection on both the apparel andotherproducts. File: 8107_Press Release_EN_20240829_Final29/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Ficus Technology Holdings Limited(Incorporated in the Cayman Islands with limited liability)(Stock Code: 8107)Entering into a Cooperation Agreement with the subsidiary of China Supply and Trade GroupTo Synergise Channel and Supply Chain Resources(Hong Kong - 29 August 2024) Innovative supply chain management service provider –Ficus Technology Holdings Limited (“Ficus Technology” or the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 29 August 2024, Ficus Discovery (www.ficusdsc.com, “Ficus Discovery Platform”), the e-commerce platform operated by the Group is collaborating with Beijing New Cooperation Ruida Trade Co., Ltd.* (“Beijing Ruida”) for a period of three years. As a direct wholly-owned subsidiary of China Supply and Trade Group and an indirect wholly-owned subsidiary of China CO-OP Group Co., Ltd., Beijing Ruida is primarily engaged in provision of supply chain services, operation of supermarket and other business in the retail industry.Leveraging its supply chain resources, including access to local products and local brands as well as its extensive supermarket and retail network, Beijing Ruida will provide products and supply chain services to Ficus Discovery Platform. This strategic partnership will allow both parties to synergise their channel resources, enhance product diversity and expand customer base across both online and offline channels. About Ficus Discovery Platform Ficus Discorvery Platform is an e-commerce platform operated by the Group, utilizing a disintermediation model to establish direct connections between manufacturers and consumers (“M2LC”), thereby facilitating transactions and cultivating a long-term loyal customer base. Leveraging the Group’s extensive supply chain resources, innovative supply chain management solutions, digital marketing capabilities, authentication and traceability technologies, the Ficus Discovery Platform is well-positioned to be a trustworthy gateway for brands and manufacturers to access target customers.Mr. Chan Ting, Chairman and Executive Director of Ficus Technology Holdings Limited comments: “Ficus Discovery Platform is pleased to work with Beijing Ruida on providing products to consumers in both the e-commerc platform we operated and the retail channels of Beijing Ruida’s platform. The collaboration not only enables Ficus Discovery Platform to diversify its product offerings but, more importantly, provides the Group with valuable access to the sales channels of the China Supply and Trade Group. We are confident that this collaboration will significantly elevate Ficus Discovery Platform's presence among consumers, establishing it as the preferred destination for daily necessities. Additionally, this partnership will amplify the brand value for both parties, driving mutual growth and market influence.”- END -About Ficus Technology Holdings Limited（8107.HK）Ficus Technology Holdings Limited (formerly known as Vision International Holdings Limited) is an innovative supply chain management service provider, mainly focuses on the sales of apparel products with the provision of supply chain management services. The Group had advanced supply chain management service to include anti-counterfeit, traceability and marketing functions for brand protection on both the apparel andotherproducts. File: 8107_Press Release_EN_20240829_Final29/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Kaspi.kz (KSPI), the fintech giant from Kazakhstan, has announced its intention to participate in the privatization of Humo, one of Uzbekistan’s leading payment systems. This move is seen as a significant step in the company’s broader strategy to expand its footprint across Central Asia, further solidifying its position as a regional financial leader.The proposed acquisition of Humo would mark Kaspi.kz’s first major venture into the Uzbek market, a region that has been attracting increasing attention from global investors due to its rapid economic reforms and growing consumer base. With a robust digital ecosystem already in place in Kazakhstan, Kaspi.kz is well-positioned to leverage its technological expertise and customer-centric approach to drive growth in Uzbekistan.According to Paulius Stankevicius, CEO of Stankevicius Alternative Investment Banking, a leading global investment advisory firm, Kaspi.kz’s interest in Humo is a strong signal for the banking industry in Central Asia. Stankevicius, whose firm advises some of the world’s top financial institutions, remarked, “Kaspi.kz has consistently demonstrated its ability to innovate and capture market share through its integrated platform that combines payments, marketplace services, and financial products. Their move into Uzbekistan signals a growing confidence in the region’s economic potential and will likely spur further investments in the fintech sector.”Sean Chin MQ, investment manager of Olritz Financial Group , with over 10 years of experience in hedge fund management, shared this perspective. His firms, specializing in asset management and financial licensing across Asia and Australia, manage $149 million USD in assets. “The entry of a fintech leader like Kaspi.kz into the Uzbek market is a significant milestone. Uzbekistan presents a unique opportunity for growth, and Kaspi.kz’s strategic move will likely encourage further investments and innovations in the region’s financial services,” said Sean Chin MQ.This view is reinforced by Mikhail Lomtadze, CEO and co-founder of Kaspi.kz, who in a recent statement emphasized the strategic importance of entering the Uzbek market. “Uzbekistan represents a significant growth opportunity for us. The privatization of Humo presents a unique chance to replicate our success in Kazakhstan by offering a comprehensive ecosystem of financial services that cater to the evolving needs of Uzbek consumers,” Lomtadze noted.Industry analysts believe that Kaspi.kz’s expansion into Uzbekistan could serve as a catalyst for further consolidation in the region’s financial sector. By acquiring Humo, Kaspi.kz would gain access to a well-established payment infrastructure and a growing customer base, positioning itself as a key player in the Uzbek financial market.Moreover, this move could also set the stage for increased competition among regional and global fintech companies looking to capitalize on Uzbekistan’s ongoing digital transformation. As Uzbekistan continues to open its doors to foreign investment, the entry of a major player like Kaspi.kz could accelerate the development of the country’s financial ecosystem, providing consumers with greater access to innovative financial services.In conclusion, Kaspi.kz’s strategic interest in Humo is not only a testament to the company’s ambition but also a positive sign for the broader banking industry in Central Asia. As regional economies continue to grow and modernize, the involvement of established players like Kaspi.kz will be crucial in driving the next phase of financial innovation and inclusion.Media ContactStankevicius MGMpr@stankeviciusmgm.com29/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Kaspi.kz (KSPI), the fintech giant from Kazakhstan, has announced its intention to participate in the privatization of Humo, one of Uzbekistan’s leading payment systems. This move is seen as a significant step in the company’s broader strategy to expand its footprint across Central Asia, further solidifying its position as a regional financial leader.The proposed acquisition of Humo would mark Kaspi.kz’s first major venture into the Uzbek market, a region that has been attracting increasing attention from global investors due to its rapid economic reforms and growing consumer base. With a robust digital ecosystem already in place in Kazakhstan, Kaspi.kz is well-positioned to leverage its technological expertise and customer-centric approach to drive growth in Uzbekistan.According to Paulius Stankevicius, CEO of Stankevicius Alternative Investment Banking, a leading global investment advisory firm, Kaspi.kz’s interest in Humo is a strong signal for the banking industry in Central Asia. Stankevicius, whose firm advises some of the world’s top financial institutions, remarked, “Kaspi.kz has consistently demonstrated its ability to innovate and capture market share through its integrated platform that combines payments, marketplace services, and financial products. Their move into Uzbekistan signals a growing confidence in the region’s economic potential and will likely spur further investments in the fintech sector.”Sean Chin MQ, investment manager of Olritz Financial Group , with over 10 years of experience in hedge fund management, shared this perspective. His firms, specializing in asset management and financial licensing across Asia and Australia, manage $149 million USD in assets. “The entry of a fintech leader like Kaspi.kz into the Uzbek market is a significant milestone. Uzbekistan presents a unique opportunity for growth, and Kaspi.kz’s strategic move will likely encourage further investments and innovations in the region’s financial services,” said Sean Chin MQ.This view is reinforced by Mikhail Lomtadze, CEO and co-founder of Kaspi.kz, who in a recent statement emphasized the strategic importance of entering the Uzbek market. “Uzbekistan represents a significant growth opportunity for us. The privatization of Humo presents a unique chance to replicate our success in Kazakhstan by offering a comprehensive ecosystem of financial services that cater to the evolving needs of Uzbek consumers,” Lomtadze noted.Industry analysts believe that Kaspi.kz’s expansion into Uzbekistan could serve as a catalyst for further consolidation in the region’s financial sector. By acquiring Humo, Kaspi.kz would gain access to a well-established payment infrastructure and a growing customer base, positioning itself as a key player in the Uzbek financial market.Moreover, this move could also set the stage for increased competition among regional and global fintech companies looking to capitalize on Uzbekistan’s ongoing digital transformation. As Uzbekistan continues to open its doors to foreign investment, the entry of a major player like Kaspi.kz could accelerate the development of the country’s financial ecosystem, providing consumers with greater access to innovative financial services.In conclusion, Kaspi.kz’s strategic interest in Humo is not only a testament to the company’s ambition but also a positive sign for the broader banking industry in Central Asia. As regional economies continue to grow and modernize, the involvement of established players like Kaspi.kz will be crucial in driving the next phase of financial innovation and inclusion.Media ContactStankevicius MGMpr@stankeviciusmgm.com29/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Trio Industrial Electronics Group Limited , a leading manufacturer and distributor of advanced industrial electronic components and products in Hong Kong, is pleased to announce the consolidated interim results of the Company and its subsidiaries (the “Group”) for the six months ended 30 June 2024.

DPC Dash Ltd announces 2024 Interim Financial Results.29/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Trio Industrial Electronics Group's revenue for the six months ended 30 June 2024 amounted to HK$389.2 million; Continue to Develop ‘Greater Asia Sustainable Energy Business Circle’[Hong Kong – 28 August 2024] Trio Industrial Electronics Group Limited (“Trio Group” or the Group”, Stock code: 1710), a leading manufacturer and distributor of advanced industrial electronic components and products in Hong Kong, is pleased to announce the consolidated interim results of the Company and its subsidiaries (the “Group”) for the six months ended 30 June 2024 (“the Period”).During the Period, Europe and North America continued to be the Group’s major markets, contributing 86.2% and 7.8% of total revenue respectively. The major markets faced economic growth slowdowns caused by challenging business conditions, including high interest rates, currency depreciation, and geopolitical tensions. Customers struggled to manage surplus inventories, requiring extended efforts to reduce them amid stagnant end-user sales. Moreover, improvements in supply chain logistics and shorter delivery times encouraged customers to scale back surplus inventory levels, thereby reducing product demand.Consequently, the Group’s revenue for the Period decreased by 31.2% to approximately HK$389.2 million as compared with the corresponding period of 2023. Gross profit decreased by 43.2% year-on-year to approximately HK$67.6 million. Gross profit margin was 17.4% The Group reported a loss of approximately HK$ 25.9 million for the Period.In terms of business development, the Group’s order backlog indicates strong demand for its products, driven by a growing emphasis on health awareness, digital transformation, and the transition to sustainable energy. In addition, the Group strategically allocated additional resources to explore new opportunities in the new energy sector. The Group’s involvement in new energy initiatives included the production of essential electronic components for solar and wind power applications, as well as the development of electric vehicle chargers under our self-owned renowned “Deltrix” brand. Concurrently, in alignment with China’s influential “Belt and Road” initiative, the Group actively expanded its presence in Central Asia, notably inaugurating its first electric vehicle charging station in Almaty, Kazakhstan. The Group has been able to maintain a healthy financial position, with cash and bank balances (including restricted bank deposits) amounted to HK$120.1 million (31 December 2023: HK$77.5 million) and a current ratio at 2.6 times as at 30 June 2024. (31 December 2023: 2.9 times)Mr. Cecil Wong, the Chairman of Trio Industrial Electronics Group Limited said, “Looking forward to the second half of this year, we remain cautiously optimistic about the challenges in the business environment. Meanwhile, we also expect abundant opportunities in Central Asia with the positive development in relation to China’s ‘Belt and Road’ initiative. The Group’s overarching vision is to develop a ‘Greater Asia Sustainable Energy Business Circle’, fostering collaboration and sustainable growth across the region. To achieve this, we extend to establishing a solid presence in Uzbekistan, Hong Kong, and Southeast Asia by providing comprehensive solutions for electric vehicle charging. The Group will also establish more electric vehicle charging stations in Almaty, Kazakhstan. We aim to create an ecosystem that includes electric vehicle charging facilities, advertising services, intelligent e-commerce, car washes and convenience stores at these locations.”Mr. Wong continued, “Additionally, the Group will continue to invest in cutting-edge technologies to enhance production efficiencies and capabilities in its production facilities. Through these focused initiatives, the Group aims to strengthen its market position, harness industry growth, and uphold its dedication to excellence while meeting the diverse needs of its stakeholders.”About Trio GroupTrio Industrial Electronics Group is a manufacturer and distributor of advanced industrial electronic components and products in Hong Kong with nearly 40 years of industry experience. It is also the first Hong Kong-based industrial electronic company awarded with the Industry 4.0 maturity certificate - Industry 4.01i level. The Group’s major products include smart chargers, electro-mechanical product and switch-mode power supplies, which are widely used in smart city systems, medical and healthcare sector, as well as renewable energy field. The Group has built up a good reputation and become a trusted supplier to various international well-known brands. The majority of its clients are from Europe and the US while some from Southeast Asia and PRC. In addition, the Group and its partner have developed their own EV charger solution - Deltrix since 2017, which has been launched in the European market in response to the global efforts to develop smart economies.This press release is issued by DLK Advisory Limited on behalf of Trio Industrial Electronics Group Limited.For more details, please contact:Skye Shum - IR Managerskyeshum@triohk.com.hkPR media:DLK Advisorypr@dlkadvisory.comFile: Trio Industrial Electronics Group's revenue for the six months ended 30 June 2024 amounted to HK$389.2 million; Continue to Develop ‘Greater Asia Sustainable Energy Business Circle’28/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Achieved Record High Revenue of HK$273.6M and Net Profit of HK$67.4MFurther Penetration to Osteoporosis, Ophthalmology, and Medical Aesthetic Device Markets(28 August 2024 – Hong Kong) A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2024 (the “Period”).Key Accomplishments in the First Half of 2024During the Period, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:The Group’s revenue achieved an increase of 9.5% year-on-year (“YoY”) to approximately HK$273.6 million, whilst improving gross profit margin by 4.7 percentage points to 84.3%. Sales of Pinup® performed well, registered an increase of 12.8% YoY. The Group’s newly launched product Bogutai® achieved sales of HK$18.8 million in just four months, exceeding initial expectations.The Group achieved a record-breaking profit of approximately HK$67.4 million for the Period, representing a significant increase of 71.0% YoY, underscoring the Group’s effective strategies and operational efficiency.In January 2024, the China National Medical Products Administration (“NMPA”) granted official approval for Bogutai®’s marketing launch, marking a pivotal milestone for the Group in orthopedic disease management. Sales of Bogutai® commenced in the first half of 2024. With its superior safety profile and competitive pricing, Bogutai® promises to revolutionize global drug administration, making it more accessible and patient-friendly.In January 2024, the NMPA accepted the marketing application for Diquafosol Sodium eye drops, marking a significant advancement for the Group's ophthalmology drug portfolio. Diquafosol Sodium is anticipated to receive marketing approval in the first quarter of 2025, complementing the existing ophthalmic drug portfolio and becoming one of the first BFS Diquafosol products to be listed.The Group officially launched its first advanced skincare raw material product, Skbrella™ FN, with sales contributions expected to begin in the second half of 2024. The Group is leveraging endorsements from key opinion leaders (KOLs) in dermatology and capitalizing on the synergistic effects of Skbrella™ FN and EGF to enhance the brand's professionalism and market appeal.The Group is dedicated to the research and promotion of isavuconazonium sulfate, providing more effective antifungal treatment options for patients worldwide and improving their quality of life. During the Period, the Group completed the pharmaceutical research and is preparing to conduct pre-Bioequivalence studies, with the official market launch expected in the first half of 2027.In May 2024, the Group cooperated with Great Bay Bio (GBB) and Pebble Accelerator, a subsidiary of Tigermed to joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, we seek to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical pipeline, and ultimately, commercialization.Interim ResultsFor the Period, the Group recorded revenue of approximately HK$273.6 million, representing an increase of 9.5% YoY. The increase in revenue was mainly attributable to the sales growth of Pinup® and the Group’s newly launched product Bogutai®. Pinup® recorded an increase of 12.8% in revenue from approximately HK$124.8 million to approximately HK$140.9 million for the Period. The increase was attributable to the successfully re-selected for the centralized procurement and the procurement validity period is set for two years. The Group launched Bogutai® in March 2024 and it made an immediate financial contribution, achieving sales of HK$18.8 million in just four months. During the Period, revenue generated from GeneTime® was approximately HK$91.3 million, representing a decrease of 4.8% YoY, mainly due to the more cautious procurement strategies adopted by public hospitals due to stricter governance. Yet, the Group continues to diversify its sales channel, such as e-commerce platforms, online hospitals and pharmacies. GeneSoft® recorded a decrease in revenue from approximately HK$22.3 million to approximately HK$18.9 million, representing a decrease of 15.4% YoY. During the Period, revenue from Boshutai® declined from approximately HK$6.9 million to approximately HK$3.8 million, representing a decrease of 45.7%.Gross profit was approximately HK$230.6 million, representing an increase of 16.0% as compared with approximately HK$198.9 million for the first half of 2023. Gross profit margin increased by 4.7 percentage points YoY to 84.3%, which was attributable to the Group’s ongoing efforts in optimizing its supply chain and effectively lowering the procurement cost of API. The Group kept a tight rein on general and administrative expenses, which only accounted for 8.7% of revenue for the Period as compared with 9.4% for the same period last year. Selling and distribution expenses for the Period also decreased to 42.8% of revenue from 50.5% that of the same period last year, mainly due to the marketing expenses of Pinup® decreased and the Group’s further optimization of its salesforce. The R&D expenses increased by 77.9% YoY to approximately HK$20.9 million and the amount was in step with the Group’s product research status. The Group achieved a record-breaking profit of approximately HK$67.4 million for the Period, representing a significant increase of 71.0% YoY. The substantial profit increase, driven by the launch of a new drug, the organic growth of marketed drugs, effective marketing strategies, strict cost control and ongoing supply chain optimization. This indicates that the Group is on the right path for sustainable profit growth. ProspectsWith advancements in biotechnology and strong governmental backing, the pharmaceutical landscape in China is poised for significant growth with a compound annual growth rate (“CAGR”) of 7.5% from 2024 to 2032, according to Imarc Group. Alongside traditional pharmaceuticals, the aesthetic medical sector is gaining prominence in the market. Forecasts indicate that the aesthetic medical market is set to sustain a CAGR growth of 10% to 15% between 2024 and 2027, primarily attributing to the increasing emphasis on beauty standards and the increased spending in this domain, particularly by individuals with moderate to high incomes. The two sectors are the Group’s focus, showcasing massive expansion opportunities for the Group. Looking forward, Mr. Kingsley Leung, Chairman of Uni-Bio Science said, “We are committed to establishing a highly commercial-driven and specialized boutique R&D platform where we tightly integrate research and production under one roof. Our focus is on growing our existing products and launching new high value generic and aesthetic medical products, which we believe will continue to provide strong cash flow in the short term and support the Group’s ongoing R&D on proprietary biopharmaceutical products. This includes expanding into new areas, such as best-in-class biologics for ophthalmology and obesity.In early July 2024, we have partnered with Chongqing Minji Medical Device Co., Ltd. to tap into the medical aesthetic device sector. This collaboration grants us exclusive distribution rights for their premier products andallows us to co-develop medical device products leveraging the Group's patented core ingredient, Skbrella™ FN. This joint initiative aims to introduce China's first batch of class II medical devices utilizing fibronectin, bolstering the Group's leadership in skincare and medical aesthetics. We expect to generate over RMB30 million annually in revenue from the aesthetic medical segment within the next two to three years.To boost product awareness and market shares, we have implemented an omnichannel strategy by collaborating with internet hospitals, establishing an official GeneTime® flagship store on JD.com and partnering with over 200 online distributors. In terms of offline efforts, we have partnered with top national chain stores and retailers renowned for strong brand presence and customer trust, as we believe this provides additional opportunities for the Group to engage more potential customers. These efforts aim to further bolster product sales and establish a robust foundation for the future launch of upcoming products.To support our upcoming sales and diversified product range, our new factory in Dongguan, Guangdong, has completed construction. The factory is expected to produce up to 19 million units per year of the Group's signature products, GeneTime® and GeneSoft®, representing an annual output value exceeding RMB 1 billion. This factory also features a BFS packaging line for the production of single-dose GeneSoft® and Diquafosol Sodium Eye Drops. The BFS packaging research and archival filing are expected to conclude by 2025, with the launch of GeneSoft® and Diquafosol Sodium Eye Drops in BFS packaging anticipated in 2026.” About Uni-Bio Science Group LimitedUni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.For further information, please contact: ir@uni-bioscience.com 28/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Ficus Technology Holdings Limited(Incorporated in the Cayman Islands with limited liability)(Stock Code: 8107)Entering into a Cooperation Agreement with Shenbei Community Service CentreCo-nurturing Target Customers in Local Communities(Hong Kong - 27 August 2024) Innovative supply chain management service provider –Ficus Technology Holdings Limited (“Ficus Technology” or the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 27 August 2024, the Group has entered into a strategic cooperation agreement with the Shenbei Hao He Er Community Service Centre in Shenbei New District, Shenyang City* (瀋陽市瀋北新區瀋北好賀兒社會服務中心，”Shenbei Community Service Centre”) for a period of three years.With a mission of “Supporting Enterprises and Benefiting Citizens,” Shenbei Community Services Centre is deeply rooted in local communities, offering comprehensive services and solutions to local residents. Through various community events and interactions, Shenbei Community Services Centre gains deep understanding of local needs and consumption trends, positioning it as a trustworthy gateway to access local consumers. Through this collaboration, Shenbei Community Services Centre will promote Ficus Discovery Platform (“Ficus Discovery Platofrm”, www.ficusdsc.com), the e-commerce platform operated by the Group and products it offers. A wide range of products, including apparel, daily necessities, and cosmetics, will be offered for sale in Shenbei New District, Shenyang City.About the Ficus Discovery Platform The Ficus Discorvery Platform is an e-commerce platform operated by the Group, utilizing a disintermediation model to establish direct connections between manufacturers and consumers (“M2LC”), thereby facilitating transactions and cultivating a long-term loyal customer base. Leveraging the Group’s extensive supply chain resources, innovative supply chain management solutions, digital marketing capabilities, authentication and traceability technologies, the Ficus Discovery Platform is well-positioned to be a trustworthy gateway for brands and manufacturers to access target customers. Mr. Chan Ting, Chairman and Executive Director of Ficus Technology Holdings Limited comments: “This is a mutually beneficial collaboration, allowing the Ficus Discovery Platform and the Group’s innovative supply chain management solutions to further expand its customer base, offering genuine products to local communities through community purchasing and other means. Leverage on the local knowledges provided by Shenbei Community Service Centre and the bonding influences of local residents, Ficus Discovery Platform would have the opportunity to nurture a group of loyal and long-term customers and thus enhance the sustainability and diversify the income stream of the Group.” - END -About Ficus Technology Holdings Limited（8107.HK）Ficus Technology Holdings Limited (formerly known as Vision International Holdings Limited) is an innovative supply chain management service provider, mainly focuses on the sales of apparel products with the provision of supply chain management services. The Group had advanced supply chain management service to include anti-counterfeit, traceability and marketing functions for brand protection on both the apparel andotherproducts. File: 8107_Press Release_EN_20240827_FINAL28/08/2024 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Ficus Technology Holdings Limited(Incorporated in the Cayman Islands with limited liability)(Stock Code: 8107)Entering into a Cooperation Agreement with Shenbei Community Service CentreCo-nurturing Target Customers in Local Communities(Hong Kong - 27 August 2024) Innovative supply chain management service provider –Ficus Technology Holdings Limited (“Ficus Technology” or the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 27 August 2024, the Group has entered into a strategic cooperation agreement with the Shenbei Hao He Er Community Service Centre in Shenbei New District, Shenyang City* (瀋陽市瀋北新區瀋北好賀兒社會服務中心，”Shenbei Community Service Centre”) for a period of three years.With a mission of “Supporting Enterprises and Benefiting Citizens,” Shenbei Community Services Centre is deeply rooted in local communities, offering comprehensive services and solutions to local residents. Through various community events and interactions, Shenbei Community Services Centre gains deep understanding of local needs and consumption trends, positioning it as a trustworthy gateway to access local consumers. Through this collaboration, Shenbei Community Services Centre will promote Ficus Discovery Platform (“Ficus Discovery Platofrm”, www.ficusdsc.com), the e-commerce platform operated by the Group and products it offers. A wide range of products, including apparel, daily necessities, and cosmetics, will be offered for sale in Shenbei New District, Shenyang City.About the Ficus Discovery Platform The Ficus Discorvery Platform is an e-commerce platform operated by the Group, utilizing a disintermediation model to establish direct connections between manufacturers and consumers (“M2LC”), thereby facilitating transactions and cultivating a long-term loyal customer base. Leveraging the Group’s extensive supply chain resources, innovative supply chain management solutions, digital marketing capabilities, authentication and traceability technologies, the Ficus Discovery Platform is well-positioned to be a trustworthy gateway for brands and manufacturers to access target customers. Mr. Chan Ting, Chairman and Executive Director of Ficus Technology Holdings Limited comments: “This is a mutually beneficial collaboration, allowing the Ficus Discovery Platform and the Group’s innovative supply chain management solutions to further expand its customer base, offering genuine products to local communities through community purchasing and other means. Leverage on the local knowledges provided by Shenbei Community Service Centre and the bonding influences of local residents, Ficus Discovery Platform would have the opportunity to nurture a group of loyal and long-term customers and thus enhance the sustainability and diversify the income stream of the Group.” - END -About Ficus Technology Holdings Limited（8107.HK）Ficus Technology Holdings Limited (formerly known as Vision International Holdings Limited) is an innovative supply chain management service provider, mainly focuses on the sales of apparel products with the provision of supply chain management services. The Group had advanced supply chain management service to include anti-counterfeit, traceability and marketing functions for brand protection on both the apparel andotherproducts. File: 8107_Press Release_EN_20240827_FINAL28/08/2024 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

On August 7th, the Hang Seng Indexes Company Limited (HSIL) announced that biotech stocks have begun to show signs of improvement recently, benefiting from policy support and three consecutive months of capital inflows. With the introduction of more policies, the HS HK-listed Biotech Index has outperformed the market since July.Obviously, the positive changes revealed in HSIL’s article provide investors with a new perspective, which may also indicate that the entire pharmaceutical sector is entering a new turning point.Against the backdrop of the entire sector still being undervalued, pharmaceutical companies have marched into the financial reporting season these days, providing a window for the market to evaluate their value and predict future development.TOT BIOPHARM COMPANY LIMITED (1875. HK) (hereafter referred to as TOT BIOPHARM), which submitted its interim report recently, has shown impressive business performance. So how should we view this report card of the company?1. Financial Report Highlights: Significant Transformation Results to Achieve A TurnaroundThe highlights revealed in the company's financial report can be summarized from the following aspects.Firstly, there is strong revenue growth and impressive results in turning losses into profits.In the first half of the year, TOT BIOPHARM reported operating revenue of 520 million yuan, a year-on-year increase of 59%, showing the strong growth momentum of the company's overall business. Among them, the growth in CDMO/CMO revenue is especially noteworthy, rising up to 144% year on year to 114 million yuan, and the product sales revenue reached 400 million yuan, a year-on-year increase of 44%, mainly by ongoing strong sales of core product Pusintin® (bevacizumab injection), demonstrating the solid foundation of the company's core business.It is worth noting that the company achieved a turnaround from loss to profit during the period, with a net profit of 31.559 million yuan in the first half of the year. This transformation not only reflects the profitability of the company's business, but also enhances market confidence in its future development.Secondly, there stands the company's excellent performance to generate revenue.The company's ability to generate revenue continues to strengthen, and the net cash flow from operating activities continues to show a positive trend. The data shows that the net cash flow from operating activities of 27.801 million yuan in the first half of the year presents the company's excellent cash flow management and capital operation capabilities.The core highlight of this report lies in the significant achievements of the company's strategic transformation.This is directly reflected in the strong growth of CDMO/CMO business.In the first half of the year, this business segment achieved a revenue of 114 million yuan, a year-on-year increase of 144%. It can be seen under the exponential growth that the company has successfully nurtured explosive growth points.Secondly, the transformation fruits are also reflected in the significant increase in the company's CDMO projects and the certainty of future growth.According to the financial report, the company added 20 new projects in the first half of the year, bringing the total to 115 projects. Among the new projects, 17 were ADC; In the meantime, 2 new pre-BLA (pre-biologics license application) projects have also been added, with a total of 8 in process. These projects will be directly linked to the commercial production of future products, providing the company with a clear path for performance growth and enormous commercial potential.In addition, the company’s backlog reached184 million yuan, a year-on-year increase of 104%. This remarkable achievement not only proves the strong driving force of the company's business, but also provides a guarantee for the stable growth of its future revenue.Besides, TOT BIOPHARM also features a firm determination and strategic vision for enterprise transformation in talent allocation and team building.TOT BIOPHARM has realized rapid expansion of its professional talent team in the CDMO field, with its talent structure constantly being optimized. According to the financial report, the number of CDMO team members increased by 29% to 492 compared to the same period last year, accounting for 86% of the total number of employees in the group. Meanwhile, in its core niche of ADC CDMO, its team size has also reached a year-on-year increase of 27%. This series of data reflects the company's emphasis and investment in CDMO business.Finally, the transformation achievements are also reflected in the continuous acceleration of the company's quality management system and multiple international recognition.High standard of quality management ensures the high standards and quality of the company’s products and services. Its quality management system can meet the GMP standards of China, the United States, and Europe, and has been widely recognized by the domestic and foreign industries, which provides pass for its products and services to enter the international market, facilitating the company’s global expansion.Furthermore, high-frequency GMP audits undergone further manifest the stability and reliability of the company’s quality management system. According to the data, as of June 30, 2024, the Group underwent more than 60 GMP audits cumulatively. This included passing the EU QP audit with zero defects on the first attempt, passing the official GMP audit directly on-site in Colombia, and passing the GMP audits in Indonesia, Egypt and other countries. Furthermore, the Group assisted its customers in completing inspections by their overseas partnering MNC pharmaceutical companies and other institution on multiple occasions, and successfully collaborated with its customers in completing the licensing with high recognition.In the fiercely competitive pharmaceutical market, quality is the key to standing out for enterprises. TOT BIOPHARM continuously improves its quality management system, and its achievements fully demonstrate the company's outstanding performance in quality management, which will help the company attract more investment and cooperation opportunities, and thus promote further business development.Overall, TOT BIOPHARM's financial report reveals the company's highlights in multiple aspects. These highlights not only demonstrate the company's current business strength, but also provide solid support for the company's future sustainable development and market competitiveness.Confidence to Rally from 3 Bottoms Ahead of the Industry?The valuation of the pharma industry is often affected by compounding factors in the capital market, and the industry is facing a multitude of challenging trends formed by three bottoms: policy bottom, fundamental bottom, and sentiment bottom.From a policy bottom perspective, the government continues to increase policy support for the pharma industry, providing a stable external environment and development opportunities for the industry.Since the beginning of this year, many regions have issued intensive policies to support pharmaceutical innovation to promote the high-quality development of innovative drugs in an all-round way. And just before this, on July 30th, Shanghai also issued the "Several Opinions on Supporting the Innovative Development of the Whole Chain of the Biomedical Industry", which triggered a heated response in the market. The policy support for innovative drugs will obviously bring new opportunities to the CXO industry, which is known as the "water seller" of innovative drugs.In terms of fundamental bottom, the entire pharma industry has shown weak performance in recent years. Nowadays, with the optimization of industry structure and the improvement of innovation capabilities, the fundamentals of the pharmaceutical sector are gradually improving, and those directions with sustainable profitability are becoming the focus of capital allocation.As regards sentiment bottom, after a long period of sluggish environment, the market is gradually recovering confidence in the pharmaceutical sector, and the recovery of investor sentiment will inject momentum for the valuation repair of the sector.In this context, as an pharmaceutical company, TOT BIOPHARM shows unique advantages in the industry, especially the series of gratifying changes in its fundamentals accompanying the transformation, enabling the company's value growth to be re-examined by the market.Since it shifted to biopharmaceutical CDMO in an all-round manner in 2020, the company has established new growth points from series of actions to layout in the CDMO field. This has withstood continuous verification.Looking ahead, with the increasing demand for global pharma R&D outsourcing services under the industry background, TOT BIOPHARM is expected to further expand its market share in the CDMO business and builds a strong engine for climbing new highs in revenue. Moreover, the company has successfully collaborated with its customers in completing the licensing multiple times, laying a solid foundation for the company's expansion into international markets.Focusing on biopharmaceuticals and emerging from the ADC field, TOT BIOPHARM has established a high-level domestic commercial production line that integrates antibodies, ADC substance, and drug products, and continues to build a cutting-edge ADC CDMO technology platform, representing the company's professional capabilities and technical strength in the field of biopharmaceuticals, especially ADC. Regarding the high technical barriers in the research and production of ADC drugs, TOT BIOPHARM has established a competitive advantage in the field of ADC CDMO with its high standard production line and technology platform, consolidating the company's market position in biopharmaceutical CDMO.Biologics, a well deserved hot field nowadays, contains broad prospects in the ADC market. According to Frost&Sullivan, the global ADC market is expected to grow at a high compound annual growth rate of 30.0% from $7.9 billion in 2022 to $64.7 billion in 2030. The rapid development of the ADC track will also provide broad incremental space for the ADC CDMO business market. TOT BIOPHARM, a pharma company with a deep layout in it, will undoubtedly continue to benefit.In summary, the combination of the three bottoms has brought opportunities for the pharma industry to navigate challenges, while TOT BIOPHARM, with its core competitiveness in the industry and comprehensive advantages in track layout, holds the potential to rally ahead of the entire industry. With the improvement of the market environment and the enhancement of the company's own strength, TOT BIOPHARM is expected to achieve both excellent performance and good valuation.3. ConclusionThrough in-depth analysis of the company and its pharmaceutical sector, TOT BIOPHARM's development potential and future prospects can be clearly seen in the current market environment.The core competitiveness of TOT BIOPHARM, especially its active layout in the biopharmaceutical CDMO business, indicates that the company will occupy a more important position in the future pharmaceutical market.It is believed that TOT BIOPHARM's subsequent market performance will also be worth waiting with the continuous growth of performance and the improvement of market recognition.26/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

On August 7th, the Hang Seng Indexes Company Limited (HSIL) announced that biotech stocks have begun to show signs of improvement recently, benefiting from policy support and three consecutive months of capital inflows. With the introduction of more policies, the HS HK-listed Biotech Index has outperformed the market since July.Obviously, the positive changes revealed in HSIL’s article provide investors with a new perspective, which may also indicate that the entire pharmaceutical sector is entering a new turning point.Against the backdrop of the entire sector still being undervalued, pharmaceutical companies have marched into the financial reporting season these days, providing a window for the market to evaluate their value and predict future development.TOT BIOPHARM COMPANY LIMITED (1875. HK) (hereafter referred to as TOT BIOPHARM), which submitted its interim report recently, has shown impressive business performance. So how should we view this report card of the company?1. Financial Report Highlights: Significant Transformation Results to Achieve A TurnaroundThe highlights revealed in the company's financial report can be summarized from the following aspects.Firstly, there is strong revenue growth and impressive results in turning losses into profits.In the first half of the year, TOT BIOPHARM reported operating revenue of 520 million yuan, a year-on-year increase of 59%, showing the strong growth momentum of the company's overall business. Among them, the growth in CDMO/CMO revenue is especially noteworthy, rising up to 144% year on year to 114 million yuan, and the product sales revenue reached 400 million yuan, a year-on-year increase of 44%, mainly by ongoing strong sales of core product Pusintin® (bevacizumab injection), demonstrating the solid foundation of the company's core business.It is worth noting that the company achieved a turnaround from loss to profit during the period, with a net profit of 31.559 million yuan in the first half of the year. This transformation not only reflects the profitability of the company's business, but also enhances market confidence in its future development.Secondly, there stands the company's excellent performance to generate revenue.The company's ability to generate revenue continues to strengthen, and the net cash flow from operating activities continues to show a positive trend. The data shows that the net cash flow from operating activities of 27.801 million yuan in the first half of the year presents the company's excellent cash flow management and capital operation capabilities.The core highlight of this report lies in the significant achievements of the company's strategic transformation.This is directly reflected in the strong growth of CDMO/CMO business.In the first half of the year, this business segment achieved a revenue of 114 million yuan, a year-on-year increase of 144%. It can be seen under the exponential growth that the company has successfully nurtured explosive growth points.Secondly, the transformation fruits are also reflected in the significant increase in the company's CDMO projects and the certainty of future growth.According to the financial report, the company added 20 new projects in the first half of the year, bringing the total to 115 projects. Among the new projects, 17 were ADC; In the meantime, 2 new pre-BLA (pre-biologics license application) projects have also been added, with a total of 8 in process. These projects will be directly linked to the commercial production of future products, providing the company with a clear path for performance growth and enormous commercial potential.In addition, the company’s backlog reached184 million yuan, a year-on-year increase of 104%. This remarkable achievement not only proves the strong driving force of the company's business, but also provides a guarantee for the stable growth of its future revenue.Besides, TOT BIOPHARM also features a firm determination and strategic vision for enterprise transformation in talent allocation and team building.TOT BIOPHARM has realized rapid expansion of its professional talent team in the CDMO field, with its talent structure constantly being optimized. According to the financial report, the number of CDMO team members increased by 29% to 492 compared to the same period last year, accounting for 86% of the total number of employees in the group. Meanwhile, in its core niche of ADC CDMO, its team size has also reached a year-on-year increase of 27%. This series of data reflects the company's emphasis and investment in CDMO business.Finally, the transformation achievements are also reflected in the continuous acceleration of the company's quality management system and multiple international recognition.High standard of quality management ensures the high standards and quality of the company’s products and services. Its quality management system can meet the GMP standards of China, the United States, and Europe, and has been widely recognized by the domestic and foreign industries, which provides pass for its products and services to enter the international market, facilitating the company’s global expansion.Furthermore, high-frequency GMP audits undergone further manifest the stability and reliability of the company’s quality management system. According to the data, as of June 30, 2024, the Group underwent more than 60 GMP audits cumulatively. This included passing the EU QP audit with zero defects on the first attempt, passing the official GMP audit directly on-site in Colombia, and passing the GMP audits in Indonesia, Egypt and other countries. Furthermore, the Group assisted its customers in completing inspections by their overseas partnering MNC pharmaceutical companies and other institution on multiple occasions, and successfully collaborated with its customers in completing the licensing with high recognition.In the fiercely competitive pharmaceutical market, quality is the key to standing out for enterprises. TOT BIOPHARM continuously improves its quality management system, and its achievements fully demonstrate the company's outstanding performance in quality management, which will help the company attract more investment and cooperation opportunities, and thus promote further business development.Overall, TOT BIOPHARM's financial report reveals the company's highlights in multiple aspects. These highlights not only demonstrate the company's current business strength, but also provide solid support for the company's future sustainable development and market competitiveness.Confidence to Rally from 3 Bottoms Ahead of the Industry?The valuation of the pharma industry is often affected by compounding factors in the capital market, and the industry is facing a multitude of challenging trends formed by three bottoms: policy bottom, fundamental bottom, and sentiment bottom.From a policy bottom perspective, the government continues to increase policy support for the pharma industry, providing a stable external environment and development opportunities for the industry.Since the beginning of this year, many regions have issued intensive policies to support pharmaceutical innovation to promote the high-quality development of innovative drugs in an all-round way. And just before this, on July 30th, Shanghai also issued the "Several Opinions on Supporting the Innovative Development of the Whole Chain of the Biomedical Industry", which triggered a heated response in the market. The policy support for innovative drugs will obviously bring new opportunities to the CXO industry, which is known as the "water seller" of innovative drugs.In terms of fundamental bottom, the entire pharma industry has shown weak performance in recent years. Nowadays, with the optimization of industry structure and the improvement of innovation capabilities, the fundamentals of the pharmaceutical sector are gradually improving, and those directions with sustainable profitability are becoming the focus of capital allocation.As regards sentiment bottom, after a long period of sluggish environment, the market is gradually recovering confidence in the pharmaceutical sector, and the recovery of investor sentiment will inject momentum for the valuation repair of the sector.In this context, as an pharmaceutical company, TOT BIOPHARM shows unique advantages in the industry, especially the series of gratifying changes in its fundamentals accompanying the transformation, enabling the company's value growth to be re-examined by the market.Since it shifted to biopharmaceutical CDMO in an all-round manner in 2020, the company has established new growth points from series of actions to layout in the CDMO field. This has withstood continuous verification.Looking ahead, with the increasing demand for global pharma R&D outsourcing services under the industry background, TOT BIOPHARM is expected to further expand its market share in the CDMO business and builds a strong engine for climbing new highs in revenue. Moreover, the company has successfully collaborated with its customers in completing the licensing multiple times, laying a solid foundation for the company's expansion into international markets.Focusing on biopharmaceuticals and emerging from the ADC field, TOT BIOPHARM has established a high-level domestic commercial production line that integrates antibodies, ADC substance, and drug products, and continues to build a cutting-edge ADC CDMO technology platform, representing the company's professional capabilities and technical strength in the field of biopharmaceuticals, especially ADC. Regarding the high technical barriers in the research and production of ADC drugs, TOT BIOPHARM has established a competitive advantage in the field of ADC CDMO with its high standard production line and technology platform, consolidating the company's market position in biopharmaceutical CDMO.Biologics, a well deserved hot field nowadays, contains broad prospects in the ADC market. According to Frost&Sullivan, the global ADC market is expected to grow at a high compound annual growth rate of 30.0% from $7.9 billion in 2022 to $64.7 billion in 2030. The rapid development of the ADC track will also provide broad incremental space for the ADC CDMO business market. TOT BIOPHARM, a pharma company with a deep layout in it, will undoubtedly continue to benefit.In summary, the combination of the three bottoms has brought opportunities for the pharma industry to navigate challenges, while TOT BIOPHARM, with its core competitiveness in the industry and comprehensive advantages in track layout, holds the potential to rally ahead of the entire industry. With the improvement of the market environment and the enhancement of the company's own strength, TOT BIOPHARM is expected to achieve both excellent performance and good valuation.3. ConclusionThrough in-depth analysis of the company and its pharmaceutical sector, TOT BIOPHARM's development potential and future prospects can be clearly seen in the current market environment.The core competitiveness of TOT BIOPHARM, especially its active layout in the biopharmaceutical CDMO business, indicates that the company will occupy a more important position in the future pharmaceutical market.It is believed that TOT BIOPHARM's subsequent market performance will also be worth waiting with the continuous growth of performance and the improvement of market recognition.26/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

PetroChina Posted Another Record High Operating Results for 1H 2024(26 August 2024) – PetroChina Company Limited (“PetroChina” or the “Company”, HKSE: 00857, SSE: 601857) announced its operating results for the first half of 2024. The Company strengthened market analysis and proactively responded to multiple challenges. While pursuing high-quality development, it adhered to the principle of seeking progress in a steady manner. Coordinated efforts were made to drive business development and further enhance business quality and profitability, in tandem with the initiative to promote reform, innovation, safety and environmental protection. The core oil and gas businesses and other operations remained stable and profitable, with key production indicators growing steadily. The Company achieved record high first half operating results for three consecutive years. All businesses were profitable, and the financial position remained sound.In accordance with IFRS, the Company posted operating income of RMB 1.6 trillion in the first half of 2024, representing a 5% year-on-year increase. Net profit attributable to equity holders of the Company reached RMB 88.61 billion, up 3.9% year-on-year. The annualized average return on equity amounted to 10.4%. With continuous optimization of its asset-liability structure, the Company retained a robust financial position. The debt-to-asset ratio dropped by 1.4 percentage points to 39.4% from the end of the previous year. It was the lowest first half figure for the last 14 years. Meanwhile, the debt-to-capital ratio declined by 3.9 percentage points to 11.3% from the end of the previous year. It hit the lowest level in the same period for the last 16 years. To reward shareholders, the Board of Directors decided to distribute an interim dividend of RMB 0.22 per share for the first half of 2024, with total dividend payout reaching RMB 40.26 billion. This marks the third consecutive year for the Company to pay a record high interim dividend.Results ReviewSteady enhancement in oil, gas and new energies supply capacity. As the Company remained committed to effective exploration, significant breakthroughs and discoveries were made in Tarim Basin, Sichuan Basin and Junggar Basin, leading to the discovery of several large-scale proved oil and gas reserves. It made solid progress in scientific and preliminary exploration at ultra-deep (10,000-meter) oil and gas fields. Notably, the drilling of Well-Shenditake 1 exceeded 10,000 meters, setting a new record for the deepest vertical well drilled in Asia.With an emphasis on cost-effective development, the Company strengthened investment and cost management, optimized development strategies, and prioritized capacity building based on profitability metrics. Considerable efforts were devoted to controlling the decline rates of mature oil and gas fields and improving their recovery rates. The Company's overseas asset structure was further optimized, with key projects running smoothly.In the first half of 2024, the Company's total production in oil equivalent terms increased by 1.3% year-on-year to 123 million tons. Crude oil production reached 64.45 million tons, and marketable natural gas output reached 73.18 billion cubic meters.The Company actively promoted the development of large-scale new energies bases and participated in competitive allocation of new energies approval. It newly acquired 7.25 million kilowatts of wind and photovoltaic power generation approval and signed contracts for geothermal heating services covering an area of 46.15 million square meters. In the first half of 2024, the energy output from wind and photovoltaic power plants reached 2.17 billion kilowatt-hours, and power supply for external users reached 950 million kilowatt-hours, 2.5 times and 4.5 times of the same period last year respectively.The Company further advanced the development of CCUS (carbon capture, utilization, and storage) business, and injected 0.84 million tons of CO2. The oil, gas and new energies business generated an operating profit of RMB 91.66 billion, representing a 7.2% year-on-year growth.Substantial progress in transformation and upgrading of refining, chemicals and new materials business. In response to market demands fluctuation, the Company optimized the resources of crude oil, processing load, product mix, and facility maintenance schedules. It strengthened the connection of its industrial chain operations and enhanced the mutual supply of raw materials. While maintaining high utilization rates of ethylene and aromatics facilities, the Company established PetroChina Blue Ocean New Materials Company to actively develop new chemical products and materials. Pursuant to the principles of high-end, intelligent, and green development, the Company continued to drive the transformation and upgrading of refining and chemical operations. Several key ethylene projects progressed in a smooth and orderly manner, including in Jilin Petrochemical, Guangxi Petrochemical and Dushanzi Petrochemical (Tarim Phase II ).In the first half of 2024, the Company processed a total of 0.69 billion barrels of crude oil, up 3.0% year-on-year. The output of refined products reached 60.12 million tons, up 2.1% year-on-year. The output of jet fuel and feature refined products increased by 42.4% and 10% year-on-year respectively. The production of chemical products amounted to 19.04 million tons, representing a 10.2% year-on-year growth. The output of new materials reached 1.07 million tons, representing an increase of 72.0% year-on-year. The refining, chemicals and new materials business achieved an operating profit of RMB 13.63 billion.Continued improvement in marketing capabilities of the marketing business. With in-depth market analysis and forecasting, the Company implemented customized marketing strategies. It enhanced integration of wholesale and retail operations, fuel and non-fuel products, and online and offline channels. Despite a decline in overall market demand, the Company strived to maintain a stable sales of refined products and increase its market share.With an aim to accelerate green and low-carbon transition, the Company actively promoted the development of integrated energy service stations which offer fuel, gas, hydrogen, electricity and non-fuel products. Besides, it further expanded the "Convenience Store + N" operating model to drive high-quality development of non-fuel business. As a result, the non-fuel business saw significant growth in gross profit.The Company optimized its global market layout, striving to reduce oil and gas procurement costs and enrich the variety of traded products. In addition, the export strategies for refined and chemical products were enhanced, leading to an increase in overall value of the industrial chain.In the first half of 2024, the Company's total sales volume of refined products reached 79.05 million tons. Domestic sales volume of these refined products amounted to 58.45 million tons. The marketing business achieved an operating profit of RMB 10.10 billion.Volume and profit growth in natural gas marketing business. The Company capitalized on favorable market condition presented by continuously rising natural gas demand, enhanced the coordination between supply and demand, and continuously optimized the structure of resource pool, which lowered its overall procurement costs.The Company strengthened its market expansion efforts by comprehensively improving natural gas sales channels and customer structure. While vigorously expanding into high-end and premium markets, it intensified efforts to acquire direct-sales and end-user customers. Moreover, the Company relentlessly developed gas power generation and new energies businesses in conjunction with continuous efforts in improving customer services to consolidate and boost its market share.The Company diversified the marketing strategies for spot LNG agent purchases and dedicated deals through exchange platform. The Company also enhanced online trading and redoubled efforts to pass on costs, hence effectively boosting sales volume and profitability. In the first half of 2024, the Company's natural gas sales reached 147.22 billion cubic meters, representing a 12.9% year-on-year increase. The domestic sales volume of natural gas amounted to 114.94 billion cubic meters, up 5.8% from the same period last year. The natural gas marketing business achieved an operating profit of RMB 16.81 billion, representing a 19.0% year-on-year increase.OutlookIn the second half of 2024, the global economy is expected to maintain moderate growth and the Chinese economy will remain on an upward trend. The Company will continue to promote high-quality development and adhere to the five major development strategies: innovation, resources, market, internationalization and green and low-carbon development.It will actively respond to market changes, adjust and optimize production and operation strategies on a timely basis, and maintain safe, stable, and profitable operations across oil and gas value chains and of other businesses. The Company will further enhance its development quality and profitability, striving to create greater value for its shareholders.###Additional information on PetroChina is available at the Company’s website: http://www.petrochina.com.cnIssued by PetroChina Company LimitedFor further information, please contact:PetroChina Company Limited PR Agency (Overseas media): PRChina LimitedJoanne Liu Fax: (852) 2522 9955Tel: (852) 2522 1838Email: petrochina@prchina.com.hk PR Agency (Domestic media): EverBloom Investment Consulting Co., Ltd.Di Shen Fax: (8610) 8562 3181Tel: (8610) 5166 3828Email: zhongshiyou.list@everbloom.com.cn File: [Press Release] PetroChina 2024 Interim Results26/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

To showcase Macao’s rich tourism resources and unique culture, the Macao Government Tourism Office (MGTO) officially launched the International “Experience Macao Limited Edition” campaign at an online press conference on August 26 at 11:00 AM (Beijing time). During the conference, MGTO Director Maria Helena de Senna Fernandes, along with representatives from Galaxy Entertainment Group, Melco Resorts & Entertainment, MGM China, Sands China, Wynn Macao, and SJM Holdings, detailed the event’s rules and impressive prizes. This campaign combines an online game with offline experiences, aiming to attract International visitors to explore the enchanting charm of Macao.A major highlight of the campaign is the exclusive theme song “Lovin' My Stay,” created for this campaign by the Macao Government Tourism Office (MGTO). The song is performed by MIYEON of the South Korean girl group (G)I-DLE, who also came to Macao to film the music video (MV). Through this MV, audiences can experience Macao’s unique allure in tune with MIYEON’s music.During the campaign, participants can register on the ExperienceMacaoLimitedEdition.com website and answer three questions related to Macao daily for a chance to win one of 100 “Experience Macao Limited Edition prizes” . The campaign is divided into three phases: Phase 1 from August 26 to September 4, Phase 2 from September 16 to September 25, and Phase 3 from October 7 to October 17. Participants who answer all three questions correctly will have a chance to enter the draw and win opportunities to unlock more experiences in Macao. Prizes include round-trip flights to Macao, premium accommodations, and unique experiences meticulously arranged by MGTO in collaboration with Macao’s six major integrated resorts. These experiences include cultural visits, intangible cultural heritage, Michelin-starred dining, and entertainment activities, providing winners with an unforgettable journey through Macao.Additionally, a special “Ultimate Experience Macao Limited Edition Prize” is set. Among the 100 prize winners, the participant who receives the most likes on social media by sharing their Macao experience before December 31, 2024, will win the Ultimate Experience Macao Limited Edition Prize—a 30-day free trip to Macao. The Ultimate Experience Macao Limited Edition Prize winner will have the opportunity to explore top attractions and rich culture throughout Macao, fully enjoying its endless charm.Whether you are a devoted fan of Macao or a newcomer from around the world, this interactive experience is not to be missed. For more information about the event, please follow the official Instagram account of the Macao Government Tourism Office, @visitmacao, where all winners will be announced. More details can be found on the Macao Government Tourism Office’s other official social media platforms.For more information, please visit: Official Website: ExperienceMacaoLimitedEdition.com Instagram: @visitmacaoFacebook: https://www.facebook.com/visitmacao/26/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

To showcase Macao’s rich tourism resources and unique culture, the Macao Government Tourism Office (MGTO) officially launched the International “Experience Macao Limited Edition” campaign at an online press conference on August 26 at 11:00 AM (Beijing time). During the conference, MGTO Director Maria Helena de Senna Fernandes, along with representatives from Galaxy Entertainment Group, Melco Resorts & Entertainment, MGM China, Sands China, Wynn Macao, and SJM Holdings, detailed the event’s rules and impressive prizes. This campaign combines an online game with offline experiences, aiming to attract International visitors to explore the enchanting charm of Macao.A major highlight of the campaign is the exclusive theme song “Lovin' My Stay,” created for this campaign by the Macao Government Tourism Office (MGTO). The song is performed by MIYEON of the South Korean girl group (G)I-DLE, who also came to Macao to film the music video (MV). Through this MV, audiences can experience Macao’s unique allure in tune with MIYEON’s music.During the campaign, participants can register on the ExperienceMacaoLimitedEdition.com website and answer three questions related to Macao daily for a chance to win one of 100 “Experience Macao Limited Edition prizes” . The campaign is divided into three phases: Phase 1 from August 26 to September 4, Phase 2 from September 16 to September 25, and Phase 3 from October 7 to October 17. Participants who answer all three questions correctly will have a chance to enter the draw and win opportunities to unlock more experiences in Macao. Prizes include round-trip flights to Macao, premium accommodations, and unique experiences meticulously arranged by MGTO in collaboration with Macao’s six major integrated resorts. These experiences include cultural visits, intangible cultural heritage, Michelin-starred dining, and entertainment activities, providing winners with an unforgettable journey through Macao.Additionally, a special “Ultimate Experience Macao Limited Edition Prize” is set. Among the 100 prize winners, the participant who receives the most likes on social media by sharing their Macao experience before December 31, 2024, will win the Ultimate Experience Macao Limited Edition Prize—a 30-day free trip to Macao. The Ultimate Experience Macao Limited Edition Prize winner will have the opportunity to explore top attractions and rich culture throughout Macao, fully enjoying its endless charm.Whether you are a devoted fan of Macao or a newcomer from around the world, this interactive experience is not to be missed. For more information about the event, please follow the official Instagram account of the Macao Government Tourism Office, @visitmacao, where all winners will be announced. More details can be found on the Macao Government Tourism Office’s other official social media platforms.For more information, please visit: Official Website: ExperienceMacaoLimitedEdition.com Instagram: @visitmacaoFacebook: https://www.facebook.com/visitmacao/26/08/2024 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com